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Elfect of amino acid administration on uremic muscle metabolism: A
31P-spectroscopy study. The effect of a six-month peritoneal amino acid
administration on muscle metabolism at rest and during exercise was
examined in 12 patients (4 control and 8 amino acid treated) on
continuous ambulatory peritoneal dialysis. 31P-magnetic resonance spec-
troscopy was used to measure several high-energy phosphates (PCr, Pi) in
resting muscle and during exercise and recovery. At rest, no significant
changes were detected between the non-treated (control) and the amino
acid treated (experimental) group. Before the administration of amino
acids, the exercise-induced fall in [PCr], the increase in [ADP] and [Pi]
and the pH were not significantly different in the control and experimental
group. The initial rate of PCr recovery and the calculated maximal rate of
ATP-synthesis (Qmx) for the control subjects was not significantly differ-
ent at the onset and the end of the study. In the treated group, however,
the fall in [PCrI and increase in [ADP] after exercise were significantly
lower after than before treatment, while [Pu and pH were identical. The
initial rate of PCr recovery and Q,,,,,,, were also significantly improved.
These changes indicate an improved oxidative phosphorylation under the
treatment and suggest that the impaired oxidative metabolism of the
dialysis patients could be the result of their bad nutritional state.
In uremic patients muscular weakness is a well recognized
symptom. Patients usually report being easily fatigued and having
exercise intolerance. The etiology of this uremic myopathy re-
mains unclear. Although most authors agree that a disorder of
muscle cell energy metabolism is involved, the cause of the
condition in patients with chronic renal failure has not been
identified. In these patients, subnormal muscle oxidative energy
metabolism has been recently documented by 31P nuclear mag-
netic resonance spectroscopy [1—3]. Many interrelated factors
such as altered muscle blood flow [41, anemia [5], defective muscle
metabolism of amino acids [6] and lipids [7], hormonal imbalance
[8] and insulin resistance [91 may be responsible for impaired
muscle energy production in uremia. Several authors [10—14]
demonstrated poor muscular activity with chronic malnutrition,
probably related to the protein degradation in skeletal muscle.
Patients treated with peritoneal dialysis are also at risk of
developing malnutrition for several reasons [15, 161. They fre-
quently have a poor appetite due to the continuous glucose load
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of the peritoneal dialysate. A loss of several grams of albumin via
the peritoneal fluid may occur. Systematic disease and superim-
posed illness (such as peritonitis) may be an additional cause of
malnutrition. Therefore, supplementation with intraperitoneal
solutions of amino acids has been introduced to overcome this
protein malnourishment [17, 18]. The aim of this investigation was
to study the effect of such an amino acid supplementation on the
muscle metabolism of uremic patients, using 31P magnetic reso-
nance spectroscopy.
Methods
Subjects
A total of 14 patients were included in this study (Table 1).
Patients had been on continuous ambulatory peritoneal dialysis
(CAPD) for 2 to 43 months (mean 15 months). Patients were
selected for the study when at least one of the following criteria
was present: clinical signs of malnourishment (N = 4), systemic
illness (N 9) and diabetes mellitus (N = 5). Twelve patients
completed the study. One patient was excluded because of
peritonitis and another patient was transferred to hemodialysis
because of catheter problems.
Before treatment with amino acids, all patients were using 2 or
2.5 liter peritoneal dialysis solutions containing only glucose
(Dianeal® PD1 in Twin Bag; Baxter Healthcare, Ternat, Belgium;
or Gambrosol® in Twin Bag; Gambro, Leuven, Belgium) with
three or four exchanges per day according to their needs.
For eight patients the first exchange of the day was then
replaced by a two-liter 1.1% amino acid solution (Nutrineal PD4
in Twin Bag), during a period of six months. The dwell time of the
PD4 solution was about five to six hours. Patients were asked to
eat at least two meals (that is, breakfast and lunch) during the
amino acid administration. The composition of the dialysate with
1.1% amino acid solution was as follows according to the manu-
facturer's (Baxter Healthcare) instructions (in mg/liter): histidine
714, isoleucine 850, methionine 850, leucine 1020, lysine 764,
phenylalanine 570, threonine 646, tryptophan 270, valine 1393,
tyrosine 300, alanine 951, arginine 1071, glycine 510, proline 595
and serine 510; (in mmol/liter): sodium 132, calcium 1.25, mag-
nesium 0.25, chloride 105 and lactate 40; pH was 6.7 and
osmolality 365 mOsm/liter.
31P-NMR spectroscopy
Patients were placed within a 1.5 T Magnetom (Siemens,
Erlangen, Germany) with the gastrocnemius overlying a 8-cm
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Patient Sex
Renal
disease
Age
years
Time on
dialysis
months Treatment
I F FSGS 79 ii AA
2 F DM11 67 5 AA
3 M DM11 72 40 AA4 M NS 70 18 AA
5 M NS 79 11 AA
6 M DM11 36 27 AA
7 M PAN 72 5 AA8 F APKD 61 3 AA
9 M NS 64 2 AA
10 M DM11 71 3 AA
11 M DM11 70 6 G
12 M CPN 80 39 G
13 M NS 49 43 0
14 F NS 73 3 G
NS, ne-Abbreviations are: DM II, maturity Onset diabetes melitus;
phrangiosclerosis; FSGS, focal segmental glomeruscierosis; PAN, periar-
tritis nodosa; APKD, adult polycystic kidney disease; CPN, chronic
pyelonephritis; AA, amino acid treatment; G, glucose treatment.
a Dropped Out due to peritonitis
h Transferred to hemodialysis due to catheter problems
diameter surface coil. The pulse width was chosen so as to obtain
a maximum phosphocreatine (PCr) signal. All data were collected
with a 900 ms interpulse delay. One 32-scan spectrum was
acquired from the muscle at rest. All patients were able to
perform exercise within the magnet but at two occasions, in the
beginning of the study, technical problems prevented acquistion
of the first spectra during recovery. At the end of the study one
patient was excluded from the data set because of excessive noise
in the spectra. Patients exercised by plantar fiexion of the right
ankle, lifting a maximum load at 30/mm. Thirty-two scan spectra
were collected during exercise. At the cessation of exercise the
recovery of the muscle was monitored by acquiring a total of 20
spectra with 16 scans. Data were processed by exponential multi-
plication using a 5 Hz line broadening and Fourier transforma-
tion. Signal intensities were obtained by computer fitting a sum of
Lorentzian line shapes to the measured spectrum. Concentrations
of inorganic phosphate (Pi) and PCr were calculated from the
relative signal intensities of Pi, PCr and adenosine triphosphate
(ATP) corrected for differential magnetic saturation and assum-
ing an intracellular concentration for ATP in resting muscle of 8.2
mM [1, 2]. Intracellular pH was calculated from the chemical shift
of Pi relative to PCr. The free ADP concentration and were
calculated from the creatine kinase equilibrium as described by
Kemp and Radda [19]. The initial rate of PCr recovery was
measured by linear regression of the PCr] from the end-exercise
spectrum and the first two recovery spectra [1, 21.
Statistics
Results are presented as mean (± SEM) together with the
number of individual observations. A geometric, rather than
arithmetic mean was used for all results expressed as a ratio. In
such a case, the SEM represents the mean of the upper and lower
deviation from the geometric mean [20]. The statistical signifi-
cance of differences between values was assessed by use of the
Student's t-test.
Results
In Figure 1 a typical series of spectra is shown, starting from a
spectrum at rest before the exercise followed by spectra taken with
30 second intervals during the exercise. The signal peaks are
marked with the names of the corresponding metabolites.
All metabolite concentrations and pH values are given in Table
2 and the paired exercise/resting concentrations are presented in
Table 3.
Phosphocreatine
At the onset of the study, the resting PCr concentration
averaged 30.9 0.9mM (N = 4) and 31.6 1.0 mst (N = 8) in the
control group and experimental group. These values were not
significantly different from one another (P> 0.6). Likewise, at the
end of the study, the resting PCr concentration was virtually
identical in control subjects (32.7 1.5 mM; N = 4) and patients
who received the amino acid supplementation (31.1 1.1 mM;
N = 7). No significant difference in control or treated subjects was
found between the values recorded at the onset and the end of the
study.
At the onset of the study (Table 2), the exercise-induced paired
fall in PCr concentration was similar (P > 0.2) in the control
group (15.9 1.9 mM; N = 4) and experimental group (18.4 1.2
mM; N = 6). It remained unchanged (P > 0.9) in the control
group, averaging at the end of the study 16.1 1.9 mvi (N = 4).
In the patients receiving the amino acid supplementation, how-
ever, the exercise-induced fall in PCr concentration was less
marked at the end than at the onset of the study. Paired
comparison indeed shows that such a fall was 6.1 2.0 ms't (N =
5; P < 0.05) smaller after than before treatment.
A comparable conclusion was reached when the PCr measure-
ments made at the end of the exercise were expressed relative to
the paired resting values. At the onset of the study, such a paired
exercise/resting ratio averaged 48.6 7.3% (N = 4) in the control
group and 42.1 1.8% (N = 6) in the experimental group (P>
0.3). In the former group, it remained unchanged, averaging 49.3
13.1% (N = 4) at the end of the study (P > 0.9 by paired
comparison). In the experimental group, however, the exercise/
resting ratio in PCr concentration was higher at the end than at
the start of the study: 59.4 6.6% (N = 5). This difference
achieved statistical significance whether judged from unpaired
group comparison (N = 11; P < 0.04) or paired comparison
(N = 5; P < 0.03). The latter comparison is summarized in Table
3.
At the end of the recovery period, the PCr concentration was no
more different from that recorded at rest (Table 2). Pooling all
available data, the paired difference between recovery and resting
values averaged 0.1 0.6 mivi (N = 23).
ADP
At the onset of the study, the resting ADP concentration
averaged 20.1 2.3 j.LM (N = 4) in the control group and 17.5
2.6 M (N = 7) in the experimental group (P> 0.4). It failed to
change significantly over the six months of observation, whether in
control or treated patients (P> 0.2 in both cases), with an overall
mean paired difference of 1.0 2.8 j.rM (N = 10).
At the onset of the study, the increase in ADP concentration
after exercise was not significantly different (P > 0.05) in the
control and experimental groups, whether expressed in absolute
Table 1. Patient characteristics
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Fig. 1. Representative 31P NMR spectra at rest
and during exercise with 30 second intervals. The
assignment of the peaks is indicated.
Table 2. Mean values (± SEM) for metabolic variables at rest, after exercise and after recovery in uremic patients examined before and after a
period of six months during which an amino acid supplementation was administered (treated) or not (control)
Metabolic
variable Time Patients Rest Exercise Recovery
PCr mM Before
After
Before
After
Control
Control
Treated
Treated
30.9 0.9 (4)
32.7 1.5 (4)
31.6 1.0 (8)
31.1 1.1 (7)
15.0 1.8 (4)
16.1 2.2 (4)
13.4 0.5 (6)
17.0 1.1 (7)
29.8 14 (4)
32.6 1.1 (4)
31.5 1.3 (8)
32.0 1.3 (7)
ADP p.M Before
After
Before
After
Control
Control
Treated
Treated
20.1 2.3 (4)
15.5 2.7 (4)
17.5 2.6 (7)
22.4 3.1 (7)
61.1 5.7 (4)
55.5 11.5 (4)
85.0 13.5 (6)
47.4 7.0 (7)
23.0 3.4 (4)
12.9 2.0 (4)
17.8 4.0 (7)
18.2 4.3 (7)
Pi mM Before
After
Before
After
Control
Control
Treated
Treated
4.49 0.74 (4)
3.84 0.59 (4)
4.29 0.31 (8)
5.97 0.93 (7)
23.1 2.5 (4)
16.4 2.2 (4)
26.7 5.6 (6)
34.2 5.8 (7)
4.52 0.62 (4)
3.80 0.95 (4)
3.68 0.47 (8)
4.70 0.94 (7)
pH Before
After
Before
After
Control
Control
Treated
Treated
7.033 0.009 (4)
7.015 0.032 (4)
7.007 0.016 (7)
7.075 0.034 (7)
6.817 0.053 (4)
6.801 0.014 (4)
6.867 0.053 (6)
6.779 0.063 (7)
7.030 0.026 (4)
6.924 0.039 (4)
6.991 0.045 (7)
6.991 0.045 (7)
terms (Table 2) or as the paired exercise/resting ratio (Table 3). It
averaged 57.1 8.4 jx, with a mean exercise/resting ratio of
4.06 0.51 (N = 10 in both cases).
In the control group, the exercise-induced increase in ADP
concentration was virtually identical at the onset and end of the
study, averaging 40.1 5.0 and 40.1 9.1 /xM, respectively (N =
4 in both cases). In the treated group, however, the exercise-
induced increase in ADP concentration was lower after than
before treatment. This difference already achieved statistical
significance when judged from non-paired group comparison of
either the absolute values or the exercise/resting ratio (P < 0.02 in
both cases). When the comparison was based on paired data
collected at the onset and end of the study, the exercise-induced
increment in ADP concentration was 52.1 11.8 .tM (N = 5)
lower after than before treatment (P < 0.02). After treatment, it
averaged 20.0 4.5% (N = 5) of the paired value recorded at the
onset of the study (P < 0.005).
Likewise, the exercise/resting ratio averaged, after treatment,
32.8 3.5% (N = 5; P < 0.001) of the paired value recorded at
the onset of the study (Table 3).
PCr
150 sec
120 sec
90 sec
60 sec
30 sec
Rest
Pi 7ATP ctATP fATP
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Table 3. Mean values (± SCM) for metabolic variables measured before/after the six-month study in either control or treated patients
Metabolic variable
Control patients Treated patients
Before After P Before After P
Exercise/resting PCr % 48.6 7.3 49.3 13.1 NS (4) 41.9 4.1 59.4 6.6 <0.030 (5)
Exercise/resting ADP %
Exercise Pi.ADP ip.i2
30.3 6.4
1.43 0.20
35.9 13.7
1.11 0.44
NS (4)
NS (3)
47.8 9.4
2.06 0.33
15.5 3.4
1.19 0.26
<0.001(5)
<0.025 (5)
PCr recovery mM/second 0.31 0.11 0.39 0.12 NS (3) 0.118 0.023 0.246 0.036 <0.050 (5)
Qmax mM/mm 27.0 9.5 35.7 17.2 NS (3) 10.4 2.3 26.4 3.7 <0.020 (5)
The statistical significance of the observed changes is also indicated with the number of subjects between brackets (NS = not significant).
The ADP concentration was not significantly different at rest
and after recovery, with an overall mean paired difference of 1.2
1.5 /.LM (N = 23).
Pi
The resting Pi concentration at the onset of the study was not
significantly different (P > 0.7) in the control and experimental
group, with an overall mean value of 4.4 0.3 mrvi (N = 12). Six
months later, it remained close to its initial value (P> 0.6) in the
control group. In the treated subjects, the mean resting Pi
concentration appeared somewhat higher after than before treat-
ment, with a main paired difference of 2.6 1.0 ma (N = 7; P <
0.05). Such a change was not observed in all subjects, however,
and it failed to achieve statistical significance (P > 0.15) when
expressed in relative terms (+ 28.1 20.6%) rather than in
absolute values. Moreover, the paired absolute change in resting
Pi concentration over the six months of observation was not
significantly different (P > 0.08) in the treated and control
subjects. Finally, in the treated subjects, no significant change in
resting Pi concentration (+ 1.0 1.1 mM; N = 7; P > 0.3) was
found at the end of the six months, when the measurements made
after recovery were taken in to account, rather than the resting
values.
At the onset of the study, the exercise-induced increase in Pi
concentration was not significantly different (P> 0.6 or more) in
the control and experimental groups. It averaged 20.8 3.5 mM,
with a mean exercise/resting ratio of 5.55 0.72 (N = 10 in both
cases). Comparable values were recorded six months later,
whether in the control or experimental groups. For instance, in
the latter group, the exercise-induced paired increase in Pi
concentration averaged 22.4 5.8 mrvt (N = 6) and 28.8 5.9 mM(N = 7) at the onset and end of the study, respectively. The
corresponding values for the exercise/resting ratio amounted, in
the same subjects, to 5.74 1.27 (N = 6) at the onset of the study
and 5.64 1.42 (N = 7) six months later.
The Pi concentration was not significantly different at rest and
after recovery. Pooling all available data, the paired difference
between the resting and recovery values averaged 0.2 0.3 mM
(N = 23).
pH
At rest, the pH averaged 7.02 0.01 (N = 11) at the onset of
the study. It was not significantly different (P > 0.25) in the
control and experimental groups. Six months later, the resting pH
was not significantly different from that found at the start of the
study, whether in control or treated subjects. Pooling all available
data, the paired change in resting pH represented no more than
0.03 0.03 (N = 10).
The exercise caused a highly significant fall in pH (P < 0.001),
and such a decrease was observed in all individual tests. The
exercise-induced paired fall in pH averaged 0.17 0.03 and
0.24 0.04 (N = 10 to 11) at the onset and end of the study. In
this respect, there was no significant difference whether compar-
ing control and treated subjects (at the onset or end of the study)
or comparing results obtained before or after the six months of
observation (in either control or treated patients).
No significant difference in pH was found before exercise and
after recovery, whether in control or treated subjects at the onset
or end of the study. Pooling all available data, however, the pH
after recovery was 0.06 0.02 pH units (N = 23) lower (P < 0.02)
than the paired resting value.
Phosphoiylation potential
The phosphoiylation potential or ATP/(ADP. Pi) ratio is cur-
rently judged from the Pi - ADP product, assuming a fixed ATP
concentration [3].
At the onset of the study, the resting Pi ADP product was not
significantly different (P > 0.5) in the control and experimental
groups, with mean respective values of 88.0 15.9 (N = 4) and
75.0 11.7 (N = 7)10 mM. Assuming an ATP concentration
of 8.2 mtvt, it yielded a mean phosphorylation potential of 0.114
0.011 LM' (N 11).
Six months later, the resting Pi ADP product was not signifi-
cantly changed, whether in the control subjects (P > 0.2) or
treated patients (P > 0.8).
At the end of exercise, the Pi .ADP product was considerably
higher than at rest. At the onset of the study, it averaged 1.79
0.20 /kM2 (N = 10), and was not different (P > 0.1) in the two
groups of subjects. Six months later, it failed to change signifi-
cantly (P > 0.15) in the control subjects. In the treated patients,
however, it decreased significantly (P < 0.025), representing no
more than 55.1 8.9% (N = 5) of the paired value recorded at
the onset of the study (Table 3).
After recovery, the Pi ADP product returned to basal value. It
was again not significantly different in control and treated sub-
jects, whether at the onset or end of the study. It also failed to be
significantly different before and after the observation period,
whether in control or treated patients. It averaged 78.2 14.8 and
82.6 25.8 i0 ms2 (N = 11 in both cases) at the onset of the
study and six months later, respectively.
initial rate of PCr recovery
At the onset of the study, the initial rate of PCr recovery after
exercise averaged in the uremic patients 0.22 0.06 mM/second
(N = 9). Such a value is lower (P < 0.05) than that found by
Thompson et al [2] in normal subjects, that is, 0.47 0.10
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mM/second (N = 6). It was not significantly different (P> 0.25) in
the two groups of patients examined in this study.
In the control subjects, the initial rate of PCr recovery was not
significantly different (P > 0.3 or more) at the onset and end of
the study, with a mean paired difference of 0.08 0.06 mM/secOnd
(N = 3 in both cases).
Alter amino acid treatment, however, the initial rate of PCr
recovery was significantly improved. The paired difference in
recovery rate, between after and before the treatment in the same
subjects, averaged 0.13 0.05 mM/second (N = 5; P < 0.055).
Maximum rate of ATP synthesis (Q,)
At the onset of the study, the Qmux averaged 18.8 4.6 mM/mm(N = 9). It was not significantly different (P > 0.2) in the two
groups of subjects.
In the control group, the mean Q,axwas virtually identical at
the onset (27.0 3.5 mM/mm; N = 3) and end (29.6 9.3
mM/mm; N = 4) of the study. Alter amino acid treatment, the
Qmax was significantly improved (P < 0.02). The paired ratio
after/before treatment indeed averaged 274.9 73.1% (N = 5).
Discussion
In the present study we used 31P-magnetic resonance spectros-
copy to determine whether or not nutritional rehabilitation, by
supplementing amino acids, restores the muscle protein and
energy metabolism in patients under CAPD. Several parameters
of muscle metabolism, that is, the concentrations of PCr, Pi and
intracellular pH were evaluated. In addition, we calculated the
initial rate of PCr recovery and the maximum rate of ATP
synthesis (Qmax)' which have been shown to be good parameters
for indicating mitochondrial function [3].
The rate of PCr resynthesis after exercise is considered to be a
function of mitochondrial oxidative metabolism. Impairment of
oxidative mitochondrial capacity may be caused by a shortage of
intracellular glucose or pyruvate content, necessary for delivering
the energy for PCr and ATP resynthesis. In insulin supplemented
animals, the capacity of PCr resynthesis is unaltered, which is not
the case in insulin deprived rats [21]. An increase of insulin using
the insulin clamp method increases Pi but does not change ATP,
PCr and pH [221. Diabetes is therefore not fundamentally differ-
ent from the other disease states, provided insulin is adequately
supplemented, which was the case in this study. Concerning the
effect of other disease states, it is impossible to differentiate
between different primery diseases since the number of patients is
too small and no other studies have examined this issue until now.
Our study clearly establishes that muscle metabolism in perito-
neal dialysis patients receiving a six-month amino acid supplemen-
tation was markedly different from the control group. The results
show that before amino acid supplementation the concentration
of PCr and Pi, as well as the intracellular pH, at rest and after
exercise were not different between the control and experimental
groups. At the end of the study, the values of the initial rate of PCr
recovery and the maximal ATP synthesis of the control group was
virtually identical with those calculated at the onset of the study.
By contrast, the results obtained for the amino acid treated group
show that the initial rate of PCr-resynthesis and Qmax were
significantly increased after the amino acid treatment.
The low exercise tolerance of renal failure patients is well
documented in the literature, but the physiologic etiology of this
condition is still unclear. These abnormalities in muscle function
have been attributed to various factors such as disturbances of
muscle energy metabolism resulting from a diminished substrate
supply or to a reduced oxygen delivery secondary to anemia
and/or to insufficient blood flow to the muscle during exercise [4,
5], defective muscle metabolism of amino acids [6], insulin
resistance leading to a reduction of muscle glucose utilization as
energy source [9], peripheral neuropathy [23], impaired metabo-
lism of vitamin D and excess of parathyroid hormone [81. Thomp-
son et al [3] reported that a mitochondrial defect is apparently
present only in dialyzed patients and not those yet to be dialyzed,
therefore suggesting that a substance essential for normal mito-
chondrial function is removed during dialysis. Bergstrom et a!
reported low concentrations of several essential amino acids and
high concentrations of non-essential amino acids in uremic pa-
tients [6]. The latter changes were reported in both non-dialyzed
patients and in those treated with intermittent hemodialysis. More
abnormalities in the plasma and intracellular amino acid patterns,
however, were found in the dialyzed patients than in the non-
dialyzed patients. This indicates that dialysis may further aggra-
vate the disturbances in protein metabolism of uremia. The
authors also suggested a loss of protein and amino acids in the
dialysis fluid as a cause of AA disturbance. This abnormal amino
acid pattern bears similarities to findings in malnutrition. Gupta et
al [10] demonstrated that in malnourished children, muscular
activity was significantly reduced in moderate and severe grade
malnutrition. This finding of poor muscular activity in chronic
malnutrition may be related to the protein degradation in skeletal
muscle resulting in a release of amino acids and enzymes, and
hence an alteration of protein and energy metabolism in muscle.
Impaired oxidative phosphorylation was also reported in patients
with chronic respiratory disease and was attributed to malnutri-
tion [11]. In addition, Palange et al [12], concluded that in patients
with chronic obstructive pulmonary disease (COPD), malnutrition
significantly affects muscle aerobic capacity and exercise toler-
ance. Malnutrition has also been associated with changes in
cardiac metabolism and performance due to impairment of the
cardiac mitochondrial oxidative phosphorylation in rats on a
restricted diet [13]. Pichard et a! [14] observed low PCr, normal Pi
and high ADP in resting muscle of rats with chronic starvation
using 31P-spectroscopy, and attributed these changes to alteration
in the composition of the muscle fibers.
Since peritoneal dialysis is also associated with metabolic and
nutritional abnormalities, the role of nutritional factors contrib-
uting to the malfunction of muscle cells in these patients should
not be underestimated. These abnormalities are due to the
combined effects of uremia per se, catabolism, treatment induced
amino acid losses into the dialysate, poor appetite possibly
reflecting insufficient removal of small solutes and recurrent
episodes of peritonitis. Signs of protein-energy malnutrition are
common, especially in patients with minimal or no residual renal
function. The use of amino acid-based dialysis fluid may provide
new opportunities for compensation of dialytic losses of protein
and amino acids, normalization of essential amino acids, supple-
mentation of inadequate dietary protein intake, and improvement
of the nutritional status in CAPD patients. Infusion of essential
amino acids during peritoneal dialysis has already demonstrated
an improvement of the nitrogen balance, suggesting that the
infused amino acids are used for protein synthesis [6]. Measure-
ments of plasma amino acid concentration using the Nutrineal
1.1% solution has been performed previously. Faller eta! [24] did
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not observe a significant change of the plasma amino acid
concentration after three months of supplementation. Kopple et
a! [251 showed in increase of the essential amino acids histidine,
valine, threonine and serine. The other factors that theoretically
may influence muscle dysfunction (such as vitamin D deficiency,
hyperparathyroidism and insulin resistance) are difficult to exam-
ine using the present experimental set-up. They seem, however, to
play a secondary role, since all patients irrespective of their
underlying kidney disease or PTH state responded in the same
way to the amino acid administration.
The result of this study confirms that disturbed muscle metab-
olism in uremia, especially in CAPD patients, is due to a defective
oxidative phosphorylation. The correction of this anomaly by
amino acid treatment in contrast to the glucose treatment,
suggests that the poor muscular activity in CAPD patients may be
related to the state of nutrition of the patient caused by low or
inadequate metabolism of amino acids. This study indicates that
supplementing amino acids can result in an improvement in the
mitochondrial muscle function. Whether this improvement of
muscle function will also result in an increase of muscle mass and
in improved survival or quality of life needs to be examined by a
long-term study.
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